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Key messages 
 Poor access to GPs may influence the route to a cancer diagnosis 
 Longer travel to a GP increased the risk of diagnosis via less desirable routes 
 Longer travel to a GP reduced the risk of diagnosis via more desirable routes 
 
Abstract 
Background 
Poor geographical access to health services and routes to a cancer diagnosis such as 
emergency presentations have previously been associated with worse cancer outcomes. 
However, the extent to which access to general practitioners (GPs) determines the route 
that patients take to obtain a cancer diagnosis is unknown. 
 
Methods 
We used a linked dataset of cancer registry and hospital records of patients with a 
cancer diagnosis between 2006 and 2010 across eight different cancer sites. Primary 
outcomes were defined as ‘desirable routes to diagnosis’ (screen-detected and two 
week wait (TWW) referrals), and ‘less desirable routes’ (emergency presentations and 
death certificate only (DCO)). All other routes (GP Referral, Inpatient Elective and Other 
Outpatient) were specified as the reference category. Geographical access was 
measured as travel time in minutes from patients to their GP, and multinomial logistic 
regression was used to estimate Relative Risk Ratios (RRR). 
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Results 
Longer travel was associated with increased risk of diagnosis via emergency and DCO, 
but decreased risk of diagnosis via screening and TWW. Patients travelling over 30 
minutes had the highest risk of a DCO diagnosis, which was statistically significant for 
breast, colorectal, lung, prostate, stomach and ovarian cancers (compared to patients 
with travel times < 10 minutes: RRR 5.89, 7.02, 2.30, 4.75, 10.41; p<0.01 and 3.51, 
p<0.05). 
 
Discussion 
Poor access to general practitioners may discourage early engagement with health 
services, decreasing the likelihood of screening uptake, and increasing the likelihood of 
emergency presentations. Extra effort is needed to promote early diagnosis in more 
distant patients. 
 
Keywords: Early diagnosis, emergency admissions, health services accessibility, primary 
health care, screening 
 
Introduction 
Identifying the pathways that lead to a cancer diagnosis is an important approach to 
improving access to care and consequent health outcomes such as survival. This is 
because the route that a patient takes to obtain a cancer diagnosis has been shown to 
predict survival (1,2). Routes such as emergency presentations are associated with poorer 
4 
 
survival (2), whereas tumours detected via screening programmes generally have better 
outcomes (3,4). There is also evidence associating increases in the use of two week wait 
(TWW) referrals by general practitioners (GPs) with better cancer survival (5). 
 
In addition to the potential effects on survival, there are likely cost-effectiveness benefits 
or losses associated with specific diagnostic routes. Emergency presentations represent 
approximately 65% of all hospital bed-days in England, incurring heavy costs and causing 
significant disruption to planned inpatient admissions (6). They also account for an 
estimated 24% of all cancer diagnoses in England, ranging from around 5% in breast 
cancer to 62% in cancers of the central nervous system (1). Two specific diagnostic routes 
have been credited with the reduction of emergency admissions; diagnosis following 
screening for certain cancers, and TWW referrals from GPs. The former increases the 
chances of cancer detection at the earliest stage whilst the latter helps ensure that patients 
with expedited GP referrals are seen by a specialist within a two-week window. The decline 
in emergency presentations England for lung cancer from 39% in 2006 to 35% in 2013 
may be due to increases in TWW referrals from 22% to 28% in the same period (7). 
Similarly, the 3% drop in colorectal cancer emergency presentations may be explained by 
corresponding 4% and 10% increases in TWW referrals and screen detected diagnosis (8). 
 
Preventing avoidable emergency admissions and other less desirable routes to diagnosis 
requires an understanding of factors that determine diagnostic routes. Some emergency 
admissions are unavoidable as they may result from aggressive tumours that require 
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sudden critical attention; these do not necessarily indicate failure of earlier diagnosis 
(9,10). However, many emergency admissions are potentially avoidable and are likely 
related to a combination of factors that operate at patient and health services levels. 
Patient level factors such as being elderly, female, ethnic minority and deprived have been 
associated with higher risk of emergency admissions (9,11). Health system level factors 
such as difficulties in obtaining GP appointments are also associated with increase in 
emergency visits (12,13). Geographical access to services may also determine how a 
cancer diagnosis is obtained. Two previous studies showed an association between poor 
access to hospital, screening sites and reduced participation in screening programmes 
(14,15). Another study found that hospital inaccessibility increased the odds of a post-
mortem cancer diagnosis (16).  
 
There is limited evidence showing the relationship between access to the GP and prompt 
diagnosis. Previous work has shown that primary care inaccessibility impinges on GP 
consultation rates (17), suggesting that poor access may determine how a cancer 
diagnosis is attained; by lowering the likelihood of patients to engage with early diagnosis 
services, or by influencing GPs decision to refer patients to secondary care for diagnosis 
(17,18). 
 
This is the first study to use individual patient level data to comprehensively examine and 
compare how travelling time to a GP is associated with the routes that patients take for a 
cancer diagnosis. We hypothesise that poor access will increase the likelihood of 
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obtaining a diagnosis from less desirable routes (emergency presentations and DCO), but 
will increase the likelihood of obtaining a diagnosis from routes of better prognosis 
(screen-detected and TWW). It is hoped the findings will support early diagnosis efforts, 
by showing how the prospect of longer travel determines how patients’ engage with 
services for a cancer diagnosis, or GPs decisions to make onward referrals to secondary 
care. 
 
Methods 
The analysis uses cancer registry records of cases diagnosed between 2006 and 2010 in 
England. Eight cancer sites were examined; breast (International Classification of Disease 
(ICD)-10 code C50), brain (C71), cervical (C53), colorectal (C18- C20), lung (C33-34), 
ovarian (C56-57), prostate (C61) and stomach (C16). These were selected to include rare 
and common tumours, those that are amenable to screening, and tumours with varying 
degrees of diagnostic difficulty (19). Each record contained information on the route that 
the patient would have taken prior to obtaining a diagnosis. This was obtained by linking 
data from routine datasets to provide details on interactions between the patient and 
health services before the diagnosis (1,20).  
 
Record level data were retrieved from English cancer registries, and linked with Hospital 
Episodes Statistics (HES) inpatient and outpatient records, the National Cancer Waiting 
Times (NCWT) monitoring dataset, and the NHS Breast Screening Programme data. 
Screening information for cervical cancer was obtained from screening status held by 
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cancer registries. Up to 71 distinct route combinations were identified by categorising 
contacts between the patient and health services according to the setting of diagnosis, 
the presence of inpatient and outpatient status, and the referral route (1). These were 
aggregated to give the following seven broad routes; screen-detected, TWW, GP Referral, 
Inpatient Elective, Other Outpatient, Emergency Presentations, DCO and Unknown. Public 
Health England (PHE) has produced a detailed description of the data linkage and 
methods (1,20). 
 
Information on routes to diagnosis, age, gender, deprivation and the Charlson 
Comorbidity Index (21) was retrieved from this linked dataset. Further linkages were made 
with estimated travel time in minutes from the patients’ home to their GP of registration. 
These travel times were computed using the Spatial Analyst module of the Geographical 
Information System (GIS) software (ArcGIS 10.3, Esri Inc.). Road travel time was selected 
as the most appropriate measure of accessibility because over 87% of cancer patients 
travel to hospital by motor vehicle (22).  
 
The outcome variable was coded into five categories: the two less desirable routes to 
diagnosis, ‘emergency presentations’ and ‘DCO’; the two routes associated with good 
prognosis, ‘TWW’ and ‘screen-detected’; and ‘all other routes’, which included routes such 
as ‘inpatient elective’, ‘other outpatients’ and ‘non-urgent GP referrals’. Patients with 
unknown routes and with secondary tumours were excluded from the analysis. 
 
8 
 
Data were analysed using Stata Version 13 (23). For the primary analysis, estimated travel 
times were grouped into four categories; ‘<10 minutes’, ’>10-20 minutes’, ’>20-30 
minutes’ and ‘>30 minutes’. Multinomial logistic regression was used to simultaneously 
estimate the association between travel time and each primary outcome relative to the 
reference group which was set as ‘all other routes’. The models were adjusted for 
potentially confounding variables deemed to be associated with travel times and the 
outcomes: age, deprivation, comorbidity, and gender (where applicable). Relative risk 
ratios (RRRs) and 95% confidence intervals (CI) were computed for all models.  
 
In a sensitivity analysis to test for trend, travel times were modelled as a continuous 
variable, and a relative risk ratio of each outcome relative to the reference group was 
calculated for every ten minutes increase in travel time. 
 
Results 
We identified 737,495 unique records with a primary diagnosis of the specified cancers in 
England diagnosed between 2006 and 2010 (Table 1). An estimated 88% of the population 
had access to their GPs within an estimated 10-minute drive (Table 1). Those with the 
poorest access (over 30 minutes) comprised of just 0.7% of the population. Routes to 
diagnosis varied considerably by tumour type. For example, breast cancer had the lowest 
percentage of emergency presentations and brain cancer had the highest; 4.5% and 63% 
respectively. Lung cancer had the highest percentage of DCOs with 0.5% being diagnosed 
post mortem (Table 1).  
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Longer travel was associated with increased likelihood of both emergency presentations 
(Table 2) and DCO routes (Table 3). The relative risk ratios progressively increased from 
the lowest travel time category to the highest. For example, for colorectal cancer, 
increases in travel time from <10.0 minutes to 10.1-20.0, 20.1-30.0 and >30.0 minutes, 
were independently associated with increased  relative risk ratios of emergency diagnosis, 
relative to the reference category, of RRR 1.01, p=0.62, RRR 1.22, p<0.01, and RRR 1.39, 
p<0.01, respectively (Table 2). 
 
The relative risk ratios were highest when the outcome was DCO. For example, among 
stomach cancer patients, an increase in travel time from 10 minutes or less to  over 30 
minutes led to a tenfold increase in likelihood of having a DCO diagnosis (RRR 10.41, 
p<0.01) (Table 3). Corresponding findings were a sevenfold (RRR 7.02, p<0.01), and a 
sixfold (RRR 5.89, p<0.01) elevated risk for colorectal and breast cancer patients 
respectively (Table 3). The RRRs for cervical cancer when the outcome was DCO could not 
be estimated due to small numbers.  
 
In contrast to the above findings, longer travel time was associated with a lower risk of 
obtaining a diagnosis following a two week wait referral. The relative risk ratios 
progressively decreased from the lowest travel category to the highest (Table 4). The 
associations were statistically significant for breast, colorectal, lung, prostate and ovarian 
cancers; for those travelling over 30 minutes, the relative risk of diagnosis via TWW for 
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these sites were: RRR 0.64, 0.72, 0.74, 0.77, (p<0.01) and RRR 0.63 (p=0.03),  respectively 
compared to those with under 10 minutes of travel (Table 4). Longer travel was also 
associated with lower odds of diagnosis via screening for breast and colorectal cancer, 
(RRR 0.52 and RRR 0.36 (p<0.01), respectively) (Table 5). 
 
The patterns above also persisted when travel times were modelled as a continuous 
variable to test for trend (Supplementary Table S1). Taking the example of breast cancer, 
every ten minutes increase in travel time was associated with an increase in diagnosis via 
the emergency route of RRR 1.03, p<0.01 , and DCO routes RRR 1.38, p<0.01 and a decline 
in diagnosis via Two Week Wait referrals RRR 0.95, p<0.01 and screening RRR 0.97, p=0.01 
(Supplementary Table S1). 
 
Discussion 
This study provides new evidence of how access to GPs in England is associated with the 
routes that lead to a cancer diagnosis. Earlier diagnosis is recognised as an important 
approach to improving cancer survival (24), and the role of GPs is central because most 
cancer patients will present their symptoms to primary care (25). Across the eight cancer 
sites studied, longer travel to the patients GP significantly increased the likelihood of 
having a cancer diagnosis through less desirable routes such as emergency or post 
mortem diagnosis. Conversely, longer travel significantly decreased the likelihood of 
obtaining a diagnosis following routes that are associated with good prognosis such as 
screening or two week wait.  
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These findings may support the work of the National Awareness and Early Diagnosis 
Initiative (NAEDI) on achieving earlier presentation (26). Efforts to improve earlier 
diagnosis should take consideration of geographical accessibility; GPs should be vigilant 
of accessibility issues that some of their patients face, as they may determine receipt of 
earlier diagnosis. 
 
This study responds to requests for evidence to establish the role of access in explaining 
variations in the mode of diagnosis (27,28). We believe it is the first study to 
simultaneously investigate four different routes to diagnosis and their association with 
geographical access to GPs. Previous studies have focused on access to hospital or 
screening sites or have examined single routes to diagnosis (13–15). One study found 
longer travel times to hospital increased the odds of post mortem diagnosis (16). Two 
previous studies showed that poor access to hospital and screening sites was associated 
with low participation in breast cancer screening programmes (14,15). Both studies used 
a smaller regional population, and so it is likely that their sample was homogenous. They 
both also estimated geographical access using road distance rather than travel time; the 
latter is a better measure because it is closest to what is experienced by patients in reality 
(29).  
 
Our results suggest that travel to the GP may be an important factor of how patients’ 
engage with all health services, and not just the services offered in primary care. This is 
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because the impact of longer travel was evident in the uptake of services such as 
colorectal and breast cancer screening that are not offered by GPs. Poor access to GPs 
may also be an indication of disconnection from primary care such as failure to register 
with a GP after relocation. Prolonged disengagement with primary care compounded by 
poor accessibility, reduces the likelihood of seeking healthcare, or of reporting symptoms 
that may be related to cancer. Although only 0.7 percent of our sample travelled longer 
than 30 minutes to see their GP, the poor outcomes amongst these patients is concerning. 
The magnitude of apparent effect for risk of diagnosis at death is particularly alarming; 
tenfold in stomach cancer (RRR 10.41, p<0.01), sevenfold in colorectal cancer (RRR 7.02, 
p<0.01), sixfold in breast cancer (RRR 5.89, p<0.01) and almost fivefold in prostate cancer 
(RRR 4.75, p<0.01). 
 
It is likely that the prospect of longer travel influences how patients interact with primary 
care for a cancer diagnosis. Geographical inaccessibility may discourage engagement with 
health services, which may decrease the likelihood of health seeking behaviour such as 
participation in screening. Poor access may also reduce the likelihood of reporting 
symptoms that may be related to cancer (30), which may consequently increasing 
emergency presentations or post mortem diagnosis. It is also likely that inaccessibility 
may influence GPs decisions to refer for further investigation; previous work has shown 
that distance to hospital may be one of the things GPs consider when making referrals 
(17,18). Conversely, it is plausible that when GPs do make urgent referrals, patients delay 
attending appointments due to barriers in access. 
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This study as several strengths. The use of a national dataset provided sufficient statistical 
power and adequate variation of explanatory variables, which enabled control for 
covariates. The large dataset also enabled comparisons across cancer sites that may vary 
in rarity and ease of detection. This also made it possible to undertake stratified analysis 
to investigate how variation in access to early diagnosis differs by cancer type. The linking 
of routine datasets made it possible to examine the four different routes in parallel, 
comparing routes associated with good and poor outcomes. Lastly, the inclusion of all 
cases registered in England over five years enhances generalisability.  
 
There are some limitations to the study. Firstly, it is a cross-sectional study hence the 
direction of causality cannot be inferred. However, it is implausible that routes to 
diagnosis would have influenced place of residence. Secondly, our measure of 
geographical access (travel time) is estimated and may not necessarily represent the 
actual journey time that each patients takes, although previous work suggests that 
estimated travel times closely match actual journeys (22). We did not consider other forms 
of transport such as public transport, but these are infrequently used for health service 
appointments, (22). Lastly, cervical screening findings should be interpreted with caution 
because this data may be of poorer quality due to variations in reporting screen detected 
records (20).  
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The most recent strategy on cancer has identified earlier diagnosis and narrowing 
inequalities as key mechanisms to improving cancer survival rates in England (31). The 
strategy has also issued a call for evaluating the impact of cancer outcomes on patients 
living different distances from a cancer centre (31). Our findings indicate that this 
evaluation should be extended to primary care. The gatekeeping role of GPs means they 
control non-emergency access to other services and therefore it is likely that issues in 
access observed in secondary care may originate from poor primary care access (32,33). 
We found that an estimated 0.7% patients experiencing the highest odds of delayed 
diagnosis are more likely to live over 30 minutes from their GP, which represents 
approximately 2,100 annual cases of all cancers diagnosed in England; based on the 
Cancer Research UK statistics of annual cancer cases in UK countries in 2015 (34). Targeted 
action on improving access amongst these patients may help meet the goals to reduce 
cancer mortality and narrow inequalities; poor access is disproportionally felt by those 
who are either elderly, have a disability or a chronic condition that renders them unable 
to drive, or are too deprived to be able to afford a car (32,35). Supporting these groups 
of patients to engage with the health services may include use of telephone consultations 
or other aspects of telehealth that have been successfully implemented in geographically 
isolated patients (36–38). 
 
Recent developments in early diagnosis awareness following the auspices of the National 
Awareness and Early Diagnosis Initiative (NAEDI) may have measurable impact on 
patients’ access to primary care for diagnosis. The dataset used in this study pre-dates 
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NAEDI’s work and therefore is an appropriate baseline against which progress on access 
to early diagnosis can be measured in future studies. Future research should examine the 
underlying mechanisms that may explain the association between longer travel and 
outcomes. Further research should also examine rural urban differences in routes to 
diagnosis, and the extent of travel time moderation on rural and urban outcomes. Rural 
areas have poorer geographical access to services (39), but this does not necessarily 
translate to higher emergency department visits (13,40), suggesting that rurality may be 
a distinct variable that measures a different parameter to travel time. This needs to be 
tested empirically.  
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Table 1 - Characteristics of the study cohort; patients with a cancer diagnosis between 2006 and 2010 in England across 
eight cancer sites. The table gives a summary by cancer site, exposure, predictor and confounding variables. 
   Number of cases (% percentage) 
  
All cancers 
No. (%) 
Breast  
No. (%)  
Colorectal  
No. (%) 
Cervical  
No. (%) 
Lung  
No. (%) 
Prostate  
No. (%) 
Stomach  
No. (%) 
Ovarian  
No. (%) 
Brain  
No. (%) 
 
Age groups 
Under 59 years 
60 - 69 years 
70 - 79 years 
80 years plus 
183,394 (24.9) 
199,941 (27.1) 
212,077 (28.7)  
142,083 (19.3)  
80,872 (44.4)  
45,380 (24.9) 
30,037 (16.5) 
25,745 (14.1) 
26,366 (17.8)    
38,967 (26.0)   
48,086 (32.1)   
36,635 (24.4)         
8,594 (74.1)       
1,094 (9.4)        
1,034 (8.9)        
877 (7.6)       
24,053 (15.3)       
42,794 (27.1)        
54,713 (34.7)        
36,213 (23.0)       
20,745 (12.9)        
54,272 (33.8)        
57,982 (36.1)        
27,669 (17.2)       
4,501 (15.1)        
6,260 (20.9)        
10,469 (35.0)        
8,668 (29.0)       
10,088  (36.8)        
6,897 (25.1)        
6,076 (22.2)       
4,374  (15.9)     
8,175 (45.3)        
4,277 (23.7)        
3,680 (20.4)        
1,902 (10.6)       
 
Gender 
Male 
Female 
363,018 (49.2) 
374,477 (50.8)  
1,366 (0.8) 
182,034 (99.2) 
83,363 (55.6) 
66,691 (44.4)             
11,599 (100.0) 89,162 (56.5)        
68,611 (43.5)       
160,668 
(100.0) 
19,440 (65.0)        
10,458 (35.0)    
27,435 (100.0) 10,385 (57.6)        
7,649 (42.4)       
 
Travel time in 
minutes to the 
GP * 
<= 10  
10.1 – 20 
20.1 – 30 
Over 30 
 650,283 (88.2) 
73,778 (10.0) 
8,639 (1.2) 
4,795 (0.6)  
159,910 (87.9)        
18,782 (10.3)        
2,167 (1.2)         
1,175 (0.7)         
132,383 (88.2)  
  15,003 (10.0) 
       1,705 (1.1)  
   963 (0.6)      
10,276 (88.6)  
1,105 (9.5) 
126 (1.1)        
92 (0.8)             
141,112 (89.4)        
14,016 (8.9)        
1,626 (1.0)        
1,019 (0.7)       
140,337 (87.4)       
17,385 (10.8)        
2,010 (1.3)        
936 (0.6)      
26,743 (89.5)        
2,675 (9.0)        
317 (1.1)        
  163 (0.6)       
24,063 (87.7)        
2,786 (10.2)        
365  (1.3)        
221 (0.8)       
15,459 (85.7)       
2,026 (11.2)        
323 (1.8)        
226 (1.3)       
 
Deprivation 
quintile 
1 least deprived 
2 
3 
4 
5 most deprived 
146,123 (19.8) 
158,288 (21.4) 
154,219 (20.9) 
144,981 (19.7) 
133,884 (18.2)  
   40,263 (22.1)        
41,430 (22.8)        
38,620 (21.2)        
33,895 (18.6)        
27,826 (15.3)       
30,754 (20.5)    
33,103 (22.1)      
32,021 (21.3)       
29,177 (19.4)        
24,999 (16.7)       
1,728 (14.9)        
2,006 (17.3)        
2,254 (19.4) 
2,575 (22.2)      
3,036 (26.2)              
21,328 (13.5)        
27,546 (17.5)        
31,853 (20.2)        
35,766 (22.7)      
41,280 (26.2)       
37,743 (23.5)        
38,355 (23.9)        
33,692 (21.0)        
28,329 (17.6)        
22,549 (14.0)       
4,805 (16.1)        
5,770 (19.3)      
6,093 (20.4)       
6,475 (21.7)        
6,755 (22.6)      
5,571 (20.3)        
5,993 (21.8)        
5,928 (21.6)        
5,411 (19.7)        
4,532 (16.5)       
3,931 (21.8)        
4,085 (22.7)       
3,758 (20.8)        
3,353 (18.6)       
2,907 (16.1)       
 
Comorbidities 
0 comorbidity 
1-2 comorbidities 
3+ comorbidities 
 624,769 (84.7) 
96,068 (13.0) 
16,658 (2.3)  
 164,919 (90.6)        
15,230 (8.4)        
1,885 (1.0)       
125,664 (83.8) 
20,636 (13.8)      
3,754 (2.5)              
10,706 (92.3) 
792 (6.8)        
101 (0.9)              
122,784 (77.8)        
29,154 (18.5)        
5,835 (3.7)       
136,301 (84.8)        
20,920 (13.0)        
3,447  (2.2)       
23,980 (80.2)       
4,911 (16.4)       
1,007 (3.4)       
24,433 (89.1)        
2,645  (9.6)       
357  (1.3)       
15,982 (88.6)        
1,780 (9.9)        
272 (1.5)       
 
Routes to 
diagnosis ** 
Screen detected 
Two week wait  
Emergency 
DCO 
Unknown 
All other routes 
61,148 (8.3) 
217,495 (29.5) 
148,237 (20.1) 
2,324 (0.3) 
25,889 (3.5) 
282,402 (38.3) 
50,843 (27.9)       
77,541 (42.6)        
8,093 (4.5)         
408 (0.2) 
7,322 (4.0) 
37,827 (20.8) 
7,445 (5.0)        
40,307 (26.8)        
36,553 (24.4) 
496 (0.3) 
4,815 (3.2) 
60,438 (40.3)               
2,860 (24.6)        
1,933 (16.7)        
1,288 (11.1) 
11 (0.1) 
414 (3.6) 
5.093 (43.9)                
 
37,780 (24.0)        
58,825 (37.3) 
837 (0.5) 
3,744 (2.4) 
56,587 (35.9)                
 
46,275 (28.8)        
14,418   (9.0)        
270   (0.2) 
7,219 (4.5) 
92,486 (57.6)       
 
6,958 (23.3)        
9,511 (31.8)       
125 (0.4) 
831 (2.8) 
12,473 (41.7)         
 
6,520 (23.8)      
8,288 (30.2)        
121 (0.4) 
1031 (3.8) 
11,475 (41.8)         
 
181 (1.0) 
11,261 (62.5)        
 56 (0.3) 
513 (2.8) 
6,023 (33.4)          
** For brevity, only 4 routes to diagnosis are shown in this table. To determine the associations between routes and travel times, the four routes were 
individually compared to the rest of routes including ‘all other routes’. 
24 
 
 
Table 2 – Association between travel times (categorical) to the GP and cases diagnosed via emergency 
presentations, for breast, colorectal, cervical, lung, prostate, stomach, ovarian and brain cancer between 
2006 and 2010. Models adjusted for age, gender (where applicable), deprivation and comorbidity. Results 
are reported as relative risk ratios (95% CI), p-value, in comparison to the reference category (<=10 
minutes). 
 
 
 
 
 
 
 
 
 
 
  
 Travel times (minutes) 
 <=10  10.1 – 20  20.1 – 30  Over 30  
Breast 1 1.18 (1.09-1.28), p<0.01 1.45 (1.18-1.79), p<0.01 1.24 (0.94-1.62), p=0.13 
Colorectal 
 
1 1.01 (0.97-1.06), p=0.62 1.22 (1.08-1.37), p<0.01 1.39 (1.19-1.62), p<0.01 
Cervical 
 
1 1.14 (0.91-1.42), p=0.26 1.69 (0.96-2.96), p=0.07 0.70 (0.30-1.63), p=0.41 
Lung 
 
1 1.09 (1.05-1.14), p<0.01 1.13 (1.01-1.27), p=0.04 1.03 (0.89-1.19), p=0.73 
Prostate 
 
1 1.01 (0.95-1.08), p=0.71 1.24 (1.05-1.45), p=0.01 1.68 (1.36-2.07), p<0.01 
Stomach 
 
1 1.06 (0.96-1.16), p=0.27 1.31 (1.01-1.72), p=0.05 1.14 (0.78-1.67), p=0.51 
Ovarian 
 
1 1.01 (0.91-1.11), p=0.90 1.17 (0.92-1.50), p=0.21 1.44 (1.05-1.98), p=0.03 
Brain 
 
1 1.07 (0.97-1.18), p=0.20 1.07 (0.84-1.36), p=0.60 1.07 (0.80-1.44), p=0.64 
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Table 3 – Association between travel times (categorical) to the GP and cases diagnosed via Death Certificate Only 
route, for breast, colorectal, cervical, lung, prostate, stomach, ovarian and brain cancer between 2006 and 2010. 
Models adjusted for age, gender (where applicable), deprivation and comorbidity. Results are reported as 
relative risk ratios (95% CI), p-value, in comparison to the reference category (<=10 minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Travel times (minutes) 
 <= 10 10.1 – 20  20.1 – 30  Over 30  
Breast 1 1.95 (1.46-2.60),  p<0.01 4.98 (3.07-8.09), p<0.01 5.89 (3.45-10.05), p<0.01 
 
Colorectal 1 1.36 (1.02-1.80), p=0.03 1.90 (0.97-3.71), p=0.06 7.02 (4.33-11.37), p<0.01 
 
Cervical 
 n/a n/a n/a 
 
Lung 1 1.21 (0.96-1.53), p=0.11 2.78 (1.76-4.38), p<0.01 2.30 (1.28-4.11), p<0.01 
 
Prostate 1 1.48 (1.04-2.10), p=0.03 2.31 (1.08-4.98), p=0.03 4.75 (2.27-9.92), p<0.01 
 
Stomach 1 2.57 (1.60-4.13), p<0.01 3.11 (0.96-10.08), p=0.06 10.41 (4.29-25.26), p<0.01 
 
Ovarian 1 1.50 (0.86-2.61), p=0.16 1.22 (0.29-5.09), p=0.78 3.51 (1.06-11.62), p=0.04 
 
Brain 1 1.62 (0.76-3.49), p=0.21 2.67 (0.63-11.21), p=0.18 1.88 (0.25-13.86), p=0.54 
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Table 4 – Association between travel times (categorical) to the GP and cases diagnosed via Two Week Wait 
referral, for breast, colorectal, cervical, lung, prostate, stomach, ovarian and brain cancer between 2006 and 2010. 
Models adjusted for age, gender (where applicable), deprivation and comorbidity. Results are reported as relative 
risk ratios (95% CI), p-value, in comparison to the reference category (<=10 minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Travel times (minutes) 
 <= 10  10.1 – 20  20.1 – 30  Over 30  
Breast 1 1.01 (0.97-1.05), p=0.77 0.87 (0.77-0.97), p<0.02 0.64 (0.55-0.74), p<0.01 
Colorectal 
 
1 1.02 (0.97-1.06), p=0.50 1.01 (0.89-1.14), p=0.87 0.72 (0.60-0.86), p<0.01 
Cervical 
 
1 1.06 (0.88-1.28), p=0.57 0.81 (0.45-1.46), p=0.48 0.64 (0.31-1.30), p=0.22 
Lung 
 
1 1.04 (0.99-1.09), p=0.14 0.98 (0.86-1.12), p=0.75 0.74 (0.62-0.88), p<0.01 
Prostate 
 
1 1.02 (0.98-1.06), p=0.30 0.97 (0.87-1.07), p=0.54 0.77 (0.65-0.91), p<0.01 
Stomach 
 
1 1.02 (0.92-1.13), p=0.68 1.05 (0.78-1.42), p=0.74 0.91 (0.59-1.40), p=0.67 
Ovarian 
 
1 1.07 (0.97-1.18), p=0.20 0.76 (0.57-1.02), p=0.07 0.63 (0.41-0.96), p<0.03 
Brain 
 
1 1.42 (0.93-2.16), p=0.10 0.99 (0.31-3.16), p=0.99 1.50 (0.47-4.83), p=0.50 
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Table 5 – Association between travel times (categorical) to the GP and cases diagnosed via screening, for breast, 
colorectal, cervical, lung, prostate, stomach, ovarian and brain cancer between 2006 and 2010. Models adjusted 
for age, gender (where applicable), deprivation and comorbidity. Results are reported as relative risk ratios (95% 
CI), p-value, in comparison to the reference category (<=10 minutes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Travel times (minutes) 
 <=10 10.1 – 20  20.1 – 30  Over 30  
 
Breast 1 1.10 (1.05-1.15), p<0.01 0.87 (0.77-0.98), p=0.03 0.52 (0.44-0.62), p<0.01 
Colorectal 1 1.12 (1.04-1.21), p=0.01 0.94 (0.75-1.19), p=0.61 0.36 (0.23-0.57), p<0.01 
Cervical 1 1.05 (0.89-1.23), p=0.60 0.70 (0.43-1.12), p=0.14 0.86 (0.50-1.48), p=0.59 
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Supplementary Table S1 – Association between travel times (continuous) to the GP and cases diagnosed via emergency 
presentations, Death Certificate Only, Two Week Wait and screen detected; for breast, colorectal, cervical, lung, prostate, 
stomach, ovarian and brain cancer between 2006 and 2010. These models are adjusted for age, gender (where applicable), 
deprivation and comorbidity Results are reported as relative risk (95% CI), p-value, for every 10 minutes increase in travel 
time. 
 
 
 
 
 
 
Emergency DCO TWW Screening 
Breast 1.07 (1.03-1.11), p<0.01 1.38 (1.28-1.49), p<0.01 0.95 (0.93-0.97), p<0.01  0.97 (0.95-0.99), p=0.01   
Colorectal 
 
1.04 (1.02-1.07), p=0.01 1.35 (1.26-1.44), p<0.01    0.98 (0.96-1.00), p<0.06      1.00 (0.96-1.04), p=0.81 
Cervical 1.04 (0.94-1.15), p=0.44 n/a 0.98 (0.90-1.08), p=0.73 0.94 (0.87-1.02), p=0.14 
Lung 1.03 (1.01-1.05), p<0.01 1.22 (1.14-1.31), p<0.01       1.00 (0.98-1.03), p=0.77  
Prostate 1.07 (1.04-1.11), p<0.01        1.35 (1.22-1.49), p<0.01         0.98 (0.96-1.00), p=0.10          
Stomach 
 
1.05 (1.00-1.11), p=0.06 1.50 (1.33-1.69), p<0.01          1.02 (0.97-1.08), p=0.41  
Ovarian 
 
1.05 (1.01-1.10), p=0.02 1.21 (1.04-1.42), p=0.02 0.97 (0.92-1.02), p=0.24  
Brain 
 
1.02 (0.98-1.07), p=0.35 1.13 (0.86-1.48), p=0.38 1.05 (0.87-1.26), p=0.65  
